Ekterly, sebetralstat
Named-patient access overview. Ekterly is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Ekterly
Ekterly (sebetralstat) is manufactured by KalVista Pharmaceuticals and indicated for Acute attacks of hereditary angioedema (HAE), oral. It is an oral small molecule (plasma kallikrein inhibitor) approved by the US FDA in 2025 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Ekterly
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Ekterly for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Ekterly is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Ekterly in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Ekterly
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.